Pérez-Morales OA, León-López DF, Bernés-Rodríguez MJ, Cuesta-Mejías T, Aguilar-Sánchez J, Padilla-Vázquez F, Escobar-De La Garma VH, Ayala-Arcipreste A, Acosta-Garcés R, Mendizabal-Guerra R

Language: Spanish
References: 26
Page: 23-31
PDF size: 799.27 Kb.

ABSTRACT

Esthesioneuroblastomas are only 3% of endonasal tumors. The importance in our area is its high tendency to invade the skull base and adjacent structures; the negative impact over the life of the patient requires handle immediately after diagnosis. Objectives: to establish the best surgical approach in the management of this disease, evaluate the type of treatment, prognostic factors and to compare them with the world literature. Methods: a retrospective, descriptive and longitudinal study of five patients with diagnosis of esthesioneuroblastomas Kadish C managed in our department, with an analysis of prognostic factors, the importance of the surgical technique, results and evolution. Results: 2 women (40 %) and 3 men (60 %) were treated; according to Kadish, five were type C. Histological outcome as rated by Hyams was 3 cases in grade I, 1 grade II case and 1 case in grade IV. One bifrontal approach was performed combined with facial degloving in 5 cases, achieving a 100 % tumor resection in 80% with check resection by endonasal endoscopy. Of these, five patients received radiotherapy management; 80% (4 cases) are alive free of disease. Conclusions: the bifrontal approach with facial degloving in Kadish stage C supported by endonasal endoscopy in all cases we believe is still the first choice of surgical treatment. Radiation therapy is an adjunct in all cases and chemotherapy in selected cases. The only well-documented prognostic factor in our series is grade Hyams .

REFERENCES

1. Muñoz Borge F, González Alonso J, Galera Ruiz H, Delgado Moreno F, Galera Davidsonc H. Avances en el diagnóstico de los tumores otorrinolaringológicos. An Pediatr 2003; 58 (5): 456-63.

2. Berger L, Luc R, Richard D. L’esthesioneuroepitheliome olfactif. Bull Assoc Fr Etude Cancer 1924;13: 410-421.

3. Broich G, Pagliari A, Ottavani F. Esthesioneuroblastoma: a general review of the cases Publisher since the discovery of the tumor in 1924. Anticancer Res 1997;17:2683-706.

4. Muñoz F, Tresserras P, Montserrat JR, Sancho FJ, Bartumeus F. Estudio retrospectivo de 11 casos de estesioneuroblastomas tratados en el Hospital Santa Creui Sant Pau entre los años 2000 y 2008 más revisión de la literatura. Neurocirugía 2011;22:401-18.

5. Gil-Carcedo E, Gil-Carcedo LM, Vallejo LA, de Campos JM. Esthesioneuroblastoma treatment. Ac Otorrinolaringol Esp 2005;56:389-95.

6. Hyams VJ. Olfactory neuroblastoma. En Hyams VJ, Batsakis JG, Michaels L. Tumors of the upper respiratory tract and ear. Washington DC: Arm For Insti Pathol 1988; 240-8.

7. Frierson HF, Ross GW, Mills SE, Frankfurter A. Olfactory neuroblastoma. Additional immunohistochemical characterization. Am J Clin Pathol 1990;94:547-53.

8. Hwank SK, Paek SH, Kim DG, Jeon YK, Chi JG, Jung HW. Olfactory neuroblastoma: survival rate and prognostic factor. J Neurooncol 2002;59:217-26.

9. Sakata K, Aoki Y, Karasawa K, Nakagawa K, Hasezawa K, Muta N, et al. Esthesioneuroblastoma. A report of seven cases. Ac Oncol 1993; 32: 399-402.

10. Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma: a clinical analysis of 17 cases. Cancer 1976;37:1571-6.

11. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a metaanalysis and review. Lancet Oncol 2001;2:683-690.

12. Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients. Laryngoscope 2009; 119: 1412-6.

13. Nichols AC, Chan AW, Curry WT, Barrer FG, Deschler DG, Lin DT. Esthesioneuroblastoma: the Massachussets eye and ear infirmary and Massachussets general hospital experience with craneofacial resection, proton beam radiation and chemotherapy: Skull base 2008;18:327-37.

14. McElroy EA. Jr, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurg 1998;42:1023-7.

15. Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993;32:706-14.

16. Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: past, present, and future?. Laryngoscope 2003;113:502-507.

17. Bachar G, Goldstein DP, Shah M, Tandon A, Ringash J, Pond G. et al. Esthesioneuroblastoma: the princess Margaret Hospital experience. Head Neck 2008;30:1607-14.

18. Díaz EM. Jr, Johnigan RH. 3rd, Pero C, El-Naggar AK, Roberts DB, Barrer JL, et al. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck 2005;27:138-49.

19. Resto VA, Eisele DW, Forastiere A, Zahurak M, Lee DJ, Westra WH. Esthesioneuroblastoma: the John Hopkins experience. Head Neck 2000;22:550-8.

20. Cohen, Z.R, Marmor, E, Fuller, G.N, DeMonte, F. Misdiagnosis of olfactory neuroblastoma. Neursurg Focus 2002;12(5):689-98.

21. Levine PA, Gallagher R, Cantrell RW. Esthesioneuroblastoma: reflections of a 21-year experience. Laryngoscope 1999;109: 1539-43.

22. Dias FL, Sa GM, Lima RA, Kligerman J, Leoncio MP, Freitas EQ, et al. Pattern of failure and outcomes in esthesioneuroblastoma. Arch Otolaryngol Head and Neck Surg 2003;129: 1186-92.

23. John R. Austin, Hazel Cebrun BS, Mathew M Kershisnik, Adel K. El-Naggar, Adam S, et al. Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: treatment results at the M.D. Anderson Cancer Center. Skull Base Surgery 1996; 6(1): 1-8.

24. McLean JN, Nunley SR, Klass C, Moore C, Müller S, Johnstone PA. Combined modality therapy of esthesioneuroblastoma. Otolaryngol Head Neck Surg 2007;136:998-1002.

25. Bradley PJ, Jones NS, Robertson I. Diagnosis and management of esthesioneuroblastoma. Curr Opin Otolaryngol Head Neck Surg 2003;11:112-8.

26. Tatagiba M, Samii M, Dankoweit-Timpe E, Aguiar PH, Osterwald L, Babu R, et al. Esthesioneuroblastoma with intracraneal extensión. Proliferative potencial and management. Arq Neuropsiquiatr 1995;53:557-86.